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A common neuropathological ﬁnding associated with both
normal ageing and a range of dementias is the presence of
senile plaques (SPs) formed from amyloid-beta (Ab) peptides
(Braak and Braak 1991; Bouras et al. 1994; Tsuboi and
Dickson 2005; Ballard et al. 2006). Their occurrence in
sufﬁcient density and distribution, together with neuroﬁbril-
lary tangles (NFTs), in histological sections of postmortem
cerebral cortex is considered diagnostic of Alzheimer’s
disease (AD) (Mirra et al. 1991; Goedert and Spillantini
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ole; DLB, dementia with Lewy bodies; FDDNP, 2-(1-{6-[(2-ﬂuoroethyl
(methyl)amino]-2-naphthyl}ethylidene)malononitrile; HSP, high-speed
pellet; HSS, high-speed supernatant; LB, Lewy body; MAB, 3-[N-mor-
pholino] propanesulphonic acid assay buffer; Me-BTA, 2-[4¢-(methyla-
mino)phenyl]-6-methylbenzothiazole; NFTs, neuroﬁbrillary tangles;
PBS, phosphate-buffered saline; PD, Parkinson’s disease; PET, positron
emission tomography; PIB, Pittsburgh Compound-B (2-[4¢-(methyl-
amino)phenyl]-6-hydroxybenzothiazole); SB13, 4-N-methylamino-4¢-
hydroxystilbene; SDS, sodium dodecyl sulphate; SPs, senile plaques.
Abstract
Amyloid containing deposits are a deﬁning neuropathological
feature of a wide range of dementias and movement dis-
orders. The positron emission tomography tracer PIB
(Pittsburgh Compound-B, 2-[4¢-(methylamino)phenyl]-6-hy-
droxybenzothiazole) was developed to target senile plaques,
an amyloid containing pathological hallmark of Alzheimer’s
disease, formed from the amyloid-b peptide. Despite the fact
that PIB was developed from the pan-amyloid staining dye
thioﬂavin T, no detailed characterisation of its interaction with
other amyloid structures has been reported. In this study, we
demonstrate the presence of a high afﬁnity binding site (Kd
 4 nM) for benzothiazole derivatives, including [3H]-PIB, on
a-synuclein (AS) ﬁlaments generated in vitro, and further
characterise this binding site through the use of radioligand
displacement assays employing 4-N-methylamino-4¢-hydr-
oxystilbene (SB13) (Ki = 87 nM) and 2-(1-{6-[(2-ﬂuoroethyl
(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP)
(Ki = 210 nM). Despite the presence of a high-afﬁnity binding
site on AS ﬁlaments, no discernible interaction of [3H]-PIB
was detected with amygdala sections from Parkinson’s dis-
ease cases containing frequent AS-immunoreactive Lewy
bodies and related neurities. These ﬁndings suggest that the
density and/or accessibility of AS binding sites in vivo are
signiﬁcantly less than those associated with amyloid-b peptide
lesions. Lewy bodies pathology is therefore unlikely to con-
tribute signiﬁcantly to the retention of PIB in positron emission
tomography imaging studies.
Keywords: a-synuclein, Alzheimer’s disease, amyloid,
imaging, Lewy body, Parkinson’s disease.
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vitam would represent a major clinical advance and one such
technique that has seen major recent advances is the ﬁeld of
amyloid imaging using positron emission tomography (PET)
(Nordberg 2007).
A series of PET radiotracer chemotypes are currently
under investigation in AD patient populations and include
[18F]-FDDNP (2-(1-{6-[(2-ﬂuoroethyl(methyl)amino]-2-na-
phthyl}ethylidene)malononitrile) (Shoghi-Jadid et al. 2002),
Pittsburgh Compound-B (2-[4¢-(methylamino)phenyl]-6-hy-
droxybenzothiazole) ([11C]-PIB) (Klunk et al. 2004), [11C]-
4-N-methylamino-4¢-hydroxystilbene (SB13) (Verhoeff et al.
2004) and [11C]-BF-227 (Kudo et al. 2007). In vitro data
suggests that these ligands have a high afﬁnity for Ab only
when it is the form of amyloid ﬁbrils (Klunk et al. 2003;
Lockhart et al. 2005). Consistent with this observation all of
the ligands, with the exception of [18F]-FDDNP, display
broadly similar cortical uptake in the frontal, parietal,
temporal and occipital lobes of AD patients. [18F]-FDDNP
additionally displayed an increased uptake in the medial
temporal lobe which is suggestive of an enhanced interaction
with NFTs (Shoghi-Jadid et al. 2002; Small et al. 2006),
even though there is a paucity of in vitro work supporting
this interpretation (Lockhart 2006).
Although the imaging tracers were developed to bind to
Ab ﬁbrils their precise molecular target is not the Ab
peptide sequence per se but rather the generic b-pleated
sheet structure that forms the amyloid folds (Fowler et al.
2007). Amyloid structures are therefore not restricted to Ab
containing lesions but can also be formed by a range of
other proteins, including some that are also common in
neurodegenerative disease, such as tau and a-synuclein
(AS), which give rise to NFTs and Lewy bodies (LBs)
respectively (Serpell et al. 2000; Berriman et al. 2003). A
number of imaging studies are now reporting data from
patient populations with diseases other than AD, including
frontotemporal lobar degeneration (Engler et al. 2008;
Rabinovici et al. 2007) and dementia with Lewy bodies
(DLB) (Bacskai et al. 2007; Johansson et al. 2007; Rowe
et al. 2007), in which NFTs and LBs, respectively, form a
signiﬁcant part of the pathological load. It is therefore
critical that a comprehensive amyloid binding proﬁle is
assembled for current PET tracers using experimental
conditions that are relevant to the low nanomolar tissue
concentrations that are attained during imaging scans
(Mathis et al. 2004; Rowe et al. 2007).
Lewy bodies and Lewy neurites are ﬁlamentous inclusions
that form in the cytoplasm of susceptible neurons and are
primarily associated with Parkinson’s disease (PD) and DLB
(Goedert 2001). However, neuropathological studies have
suggested that up to 60% of AD cases also exhibit signiﬁcant
LB pathology (Kotzbauer et al. 2001). Factors leading to the
appearance, heterogeneous morphology and neuroanatomical
location of LBs are only poorly understood (Goedert 2001;
Kotzbauer et al. 2001). The inclusions typically consist of a
central core and an outer halo, with the former containing
both amorphous material and ﬁlamentous structures. AS was
ﬁrst identiﬁed as a component of LBs and Lewy neurites
(Spillantini et al. 1997) and then immunoelectron micros-
copy, coupled with biochemical analyses, demonstrated that
it forms the ﬁlamentous structures associated with these
lesions (Baba et al. 1998; Spillantini et al. 1998). Conﬁrm-
ing their amyloid credentials, LBs can be visualised in tissue
sections using the dyes thioﬂavin S and Congo Red (Dickson
2005), although staining with the latter dye can be relatively
weak (Smid et al. 2006).
A number of previous in vitro studies interrogating the
speciﬁcity of the amyloid tracers for Ab-containing lesions
produced a somewhat confusing picture because of the use of
different experimental techniques and concentrations of
ligand. For example, initial studies using 100–1000 nM
PIB demonstrated that the ligand could bind to Ab lesions
(both classical (i.e. neuritic and cored) plaques and cerebro-
vascular amyloid) as well as NFTs (Klunk et al. 2003;
Mathis et al. 2004). However, binding assays using low
nanomolar concentrations of ligand coupled with brain
homogenates from a range of neuropathological disorders
appeared to suggest a high degree of speciﬁcity for Ab
lesions (Klunk et al. 2003). The question of binding
speciﬁcity was recently re-addressed using low nanomolar
concentrations of tritium-labelled PIB ([3H]-PIB), coupled
with high-resolution autoradiography (Lockhart et al. 2007).
This study demonstrated that at concentrations of PIB that
are directly relevant for in vivo imaging, the ligand labelled
all types of Ab-containing lesions (diffuse plaques, classical
plaques and cerebrovascular amyloid) with high afﬁnity.
Although additional labelling of NFTs was also observed, the
intensity of labelling was less than that associated with the
Ab-containing pathologies. These ﬁndings suggest that rather
than being a speciﬁc marker of AD, or speciﬁc types of
Ab-containing lesions in AD, PIB is a non-speciﬁc marker of
Ab peptide-related cerebral amyloidosis.
There have been a limited number of reports describing the
interaction of amyloid ligands with AS ﬁlaments and/or LBs.
Homogenate binding assays using the PIB-related compound
[3H]-2-(4¢-methylaminophenyl)benzothiazole (BTA-1) failed
to detect any signiﬁcant binding in one DLB case (Klunk
et al. 2003). In support of this ﬁnding, a more detailed
investigation has indicated that although high-afﬁnity bind-
ing sites were present on AS ﬁlaments generated in vitro,L B
pathology could not be labelled in tissue sections from DLB
brains or in DLB brain tissue homogenate binding assays
(Fodero-Tavoletti et al. 2007). In contrast, LB pathology is
routinely detected using compounds structurally related to
PIB, such as thioﬂavins (Conway et al. 2000), and has also
been identiﬁed using novel amyloid ligands, such as FDDNP
(Smid et al. 2006). A clear disconnect exists between these
studies and we believe that it derives in large part from the
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binding assays vs. ﬂuorescence microscopy) that differ in
sensitivity and tissue preparation.
We therefore undertook the present study, where we
have used a small panel of amyloid imaging agents to
characterise their interactions with AS ﬁlaments generated
in vitro. In addition, autoradiography on frozen human
amygdala (AMY) sections containing LB pathology was
carried out by using concentrations of [3H]-PIB relevant
for in vivo imaging. The ﬁndings reported here provide
fundamental information on the nature of the interactions
of amyloid agents with AS ﬁlaments and the associated LB
pathology.
Materials and methods
Compound names and sources
The structures of the compounds used in this study are shown
in Fig. 1 and are as follows; 2-[4¢-(methylamino)phenyl]-6-
methylbenzothiazole (6-Me-BTA-1); 2-[4¢-(methylamino)phenyl]-
6-hydroxylbenzothiazole (6-OH-BTA-1/PIB); SB13; FDDNP; and
5-bromo-2-(4-dimethylaminophenyl)benzofuran (BF1). Thioﬂavin
T was obtained from Merck Chemicals (Nottingham, UK).
The remaining compounds were custom synthesised and con-
ﬁrmed for purity by reverse phase HPLC, one-dimensional NMR
and mass spectrometry. Radiolabelled 2-[4¢-([3H]methylami-
no)phenyl]-6-methylbenzothiazole ([3H]Me-BTA-1) (84 Ci/mmol,
1 mCi/mL) and N-methyl-[3H]2-(4¢-methylaminophenyl)-6-hy-
droxylbenzothiazole ([3H]-PIB) (71 Ci/mmol, 1 mCi/mL), were
custom synthesised by Amersham Biosciences (Little Chalfont,
UK). All other chemicals were from Sigma-Aldrich (Gillingham,
UK).
Preparation of a-synuclein and formation of ﬁlaments
The expression and puriﬁcation of recombinant AS were as
described (Jakes et al., 1994; Masuda et al. 2006a). Fibrillation
reactions were performed in a shaking incubator at 37 C using
400 lMA Si n3 0m M3 - [ N-morpholino] propanesulphonic acid,
pH 7.2 [3-[N-morpholino] propanesulphonic acid assay buffer
(MAB)], containing 0.02% sodium azide, for up to 10 days (Serpell
et al. 2000).
Gel analysis of a-synuclein assemblies
Samples (20 lL) were removed at days 1, 2, 5 and 10 from the
assembly reactions, mixed with 80 lL MAB and centrifuged at
50 000 g for 30 min at 20 C. The resulting high-speed supernatant
(HSS) was removed and the high-speed pellet (HSP) re-suspended
in 100 lL MAB. HSS and HSP were mixed with sodium dodecyl
sulphate (SDS)-loading buffer and separated by SDS–polyacryl-
amide gel electrophoresis using NuPage 4–12% Bis–Tris gels
(Invitrogen, Paisley, UK). The gels were calibrated using Precision
Plus Protein Prestained Standards (BioRad, Hemel Hempsted, UK),
stained for total protein using Simply Blue Safestain (Invitrogen)
and the images captured on a ChemiGenius Bio Imaging System
(Syngene, Cambridge, UK).
Thioﬂavin T ﬂuorescence binding assay
Assays were performed in MAB using a ﬁxed concentration of
AS (1 lM) and either a ﬁxed (25 lM) or varying concentrations
of ligand (0–25 lM) as noted in the Results section. Reactions
were incubated for 1 h at 20 C before reading on an Ultra
Evolution 384 plate reader (Tecan, Reading, UK) employing a
450–505 nm ﬁlter pair. All data points were performed at least in
quadruplicate and were analysed using GRAFIT (Erithacus Soft-
ware Limited, Horley, UK) to obtain Kd values using the single
site ligand binding module.
Radioligand binding assay of a-synuclein
Assays were performed as described (Lockhart et al. 2005) using a
ﬁxed concentration of AS (200 nM) and a range of [3H]-Me-BTA-1
or [3H]-PIB concentrations (40, 16, 6.4, 2.56, 1.026, 0.4096,
0.16384 and 0.065536 nM) with the following modiﬁcations.
Reactions were performed in MAB for 1 h and non-speciﬁc binding
was determined using 50 lM Thioﬂavin T. Data were analysed
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Fig. 1 Chemical structures of compounds
used in the study. A, Thioﬂavin T; B, BTA,
R = HO (PIB)/CH3 (6Me-BTA-1)/H (BTA-1);
C, BF1; D, FDDNP; E, SB13. *Denotes
position of radiolabel on [3H]-Me-BTA-1
and [3H]-PIB. Full compound nomencla-
tures are provided in the Materials and
methods section entitled Compound names
and sources.
  2008 GlaxoSmithKline, J. Neurochem. (2008) 105, 1428–1437
1430 | L. Ye et al.using GRAFIT to obtain the apparent dissociation constant (Kd) and
the maximum number of binding sites (Bmax) using the single-site
ligand binding module.
Radioligand competition assays of a-synuclein
Assays employed a ﬁxed concentration of AS (200 nM), and
[3H]Me-BTA-1 (4 nM) as described previously (Lockhart et al.
2005), except that the reactions were performed in MAB. Reactions
were performed in MAB for 1 h and non-speciﬁc binding was
determined using 50 lM Thioﬂavin T. All data points were
performed in triplicate, and the speciﬁc binding signal in the
absence of competitor deﬁned a fractional binding of 1. Data were
analysed using GRAFIT to obtain IC50 values using 4-parameter
curve ﬁts. Ki values were calculated using the Cheng–Prusoff
equation (Cheng and Prusoff 1973): Ki =I C 50/(1 + [L]/Kd, where
[L] was the concentration of [3H] Me-BTA-1 used in the assay
(4 nM) and the Kd was from the radioligand binding assay for each
batch of AS ﬁlaments.
[3H]-PIB autoradiography
Human brain tissue was obtained from the Brain Donation Program
at Sun Health Research Institute. Two series of four consecutive
cryosections (8–10 lm thickness) of frozen AMY from each of four
cases of PD were mounted onto statically charged (plus) glass slides
prior to airtight storage with desiccants at )80 C. The ﬁrst (Slide 1)
and third (Slide 3) sections in each series were used for
histochemical analysis. The second and the fourth sections were
used in the radioligand binding studies deﬁning total (0.5 or 2 nM
[3H]-PIB) and non-displaceable (0.5 or 2 nM [3H]-PIB plus 10 lM
BTA-1) binding signals respectively.
Slides were thawed for 10 min at room temperature (25 C) prior
to incubation in phosphate-buffered saline (PBS) buffer containing
10% v/v ethanol, pH 7.2) for 15 min at 25 C. Slides were then
incubated with either [3H]-PIB or [3H]-PIB plus BTA-1 for 1 h at
25 C and the reactions terminated by consecutive 30 s incubations
in (PBS buffer containing 10% v/v ethanol, pH 7.2 (·2) and distilled
water (all at 4 C). The slides were dried under a cold air stream and
then apposed with Hyperﬁlm-3H (RPN535B: early availability
batch; Amersham Biosciences).
Sections (Slide 1) were removed from the freezer and immedi-
ately immersed in 70% ethanol for 2 min. Endogenous peroxidase
was then suppressed by immersion in 1% hydrogen peroxide for
30 min. This was followed by antigen exposure with 20% formic
acid for 1 min. After additional washes, sections were incubated
overnight in primary antibody (mouse anti-human AS, monoclonal
antibody clone LB509; Zymed, San Francisco, CA, USA), diluted
1 : 1000. Sections were then sequentially incubated in biotinylated
anti-mouse IgG, avidin–biotin peroxidase complex (ABC; Vector
Elite, Burlingame, CA, USA) and 3,3¢-diaminobenzidine (1 mg/
mL), dehydrated and mounted in Permount. For thioﬂavin S
staining, sections (Slide 3) were removed from the freezer and
immediately immersed for 30 min in 4% freshly prepared formal-
dehyde, pH 7.4. Following washes in PBS and partial drying at
25 C, the sections were defatted in 1 : 1 chloroform/ethanol for 1 h,
washed brieﬂy twice in 100% ethanol and then hydrated through
graded alcohols to water. Sections were then stained in 0.1%
thioﬂavin S for 10 min, differentiated rapidly in 80% ethanol and
coverslipped with Apathy’s medium.
Results
Formation and characterisation of a-synuclein ﬁlaments
a-Synuclein can be expressed recombinantly and assembled
into ﬁlaments that share many features of those isolated from
LBs. The relative ease of production of recombinant AS has
made it an attractive material for biochemical studies
(Crowther et al. 1998; Serpell et al. 2000), structural anal-
ysis (Serpell et al. 2000) and inhibitor screening (Masuda
et al. 2006b; Luk et al. 2007). In order to ensure that AS
ﬁlaments could be assembled in a form that was suitable for
characterisation, their properties were further assessed using
ultracentrifugation and thioﬂavin T ﬂuorescence.
a-Synuclein ﬁlaments were produced using a previously
established method (Serpell et al. 2000). The assay mixtures
were sampled after one (day 1), two (day 2), ﬁve (day 5) and
10 (day 10) days. Separation of ﬁlaments from soluble non-
amyloid forms of AS was performed using ultracentrifuga-
tion and the resulting HSS and HSP were analysed by SDS–
polyacrylamide gel electrophoresis (Fig. 2a). Gel analysis
demonstrated a time-dependent loss of soluble AS from the
HSS and its corresponding appearance in the HSP. The
incorporation of AS into the HSP plateaued by day 5.
The amyloid content of the reaction mixtures was
monitored by thioﬂavin T ﬂuorescence (Fig. 2b). Charac-
teristic of amyloid, the AS preparations produced an
enhancement in dye ﬂuorescence, which increased with
time of incubation and peaked at day 5, with no further
change evident by day 10. A binding constant for thioﬂavin
T was derived for the day 5 ﬁlaments by using a ﬁxed
concentration of polymer and varying concentrations of the
ﬂuorophore (Fig. 2c). The resulting binding isotherm was
consistent with the presence of a single class of binding
sites with a Kd value of 588 ± 2 nM. Based on the data
from these screening assays AS ﬁlaments formed after
5 days incubation were selected for further characterisation
using radioligand binding assays. Negative stain electron
microscopy conﬁrmed the ﬁlamentous nature of these
preparations (data not shown).
Radioligand binding assays
A preparation of tritium-labelled [3H]-Me-BTA1 (Fig. 1)
was used to characterise the AS ﬁlaments, as the radiotracer
has been extensively investigated with Ab ﬁbril preparations
(Lockhart et al. 2005; Ye et al. 2005). Typical data from one
of the six individual batches of day 5 AS ﬁlaments analysed
is shown in Fig. 3a. The ﬁtted binding isotherm was
consistent with the presence of a single class of binding site
and produced Kd and Bmax values of 4.62 and 0.25 nM
respectively. Composite data from the six batches demon-
strated good consistency, with Kd and Bmax values of
4.09 ± 0.82 and 0.22 ± 0.02 nM respectively (Table 1). As
the concentration of polymer used in the assays was 200 nM
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per  900 AS monomers. A tritium-labelled preparation of
2-[4¢-(methylamino)phenyl]-6-hydroxylbenzothiazole ([3H]-
PIB) was also evaluated with one batch of AS ﬁlaments and
produced values more or less identical to that obtained with
[3H]-Me-BTA1, with Kd and Bmax values of 4.16 and
0.16 nM respectively (data not shown).
The interaction of additional ligands with AS ﬁlaments
was assessed using a previously described radioligand
displacement assay format utilising [3H]-Me-BTA1 (Lock-
hart et al. 2005) (Fig. 3b). All of the competitor ligands
examined (PIB, SB13, BF1 and FDDNP) displayed a dose-
dependent displacement of the radioligand from the AS
ﬁlaments. The derived Ki values are shown in Table 1. BF1
(4.78 ± 0.43 nM) was the most potent competitor ligand
and displayed a binding afﬁnity comparable with
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Fig. 2 Characterisation of AS ﬁbrils. (a) Representative SDS–poly-
acrylamide gel electrophoresis, stained for total protein, showing time
course of polymerisation reaction. Lanes 1–4 Uncentrifuged reaction
mixture; 5–8, HSP; 9–12, HSS. The monomeric molecular weight of
AS is  15 kDa. (b) Temporal enhancement of Thioﬂavin T ﬂuores-
cence demonstrating maximal binding at day 5. (c) Saturation binding
of Thioﬂavin T to day 5 AS ﬁbrils.
(a)
(b)
Fig. 3 (a) Binding isotherm for the ligand [
3H]Me-BTA-1 with day 5 AS
ﬁbrils. Scatchard analysis is shown in inset. The Kd and Bmax values
derived from this analysis were 4.62 and 0.25 nM respectively. (b)
Radioligand competition assays. Dose–response curves showing the
fractional binding of [
3H]Me-BTA-1 to day 5 AS ﬁbrils in the presence
of competitor ligands; 4, BF1; , FDDNP; d,P I B ;h, SB13.
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around fourfold weaker than BF1 in this assay format and
this contrasts with the higher afﬁnity interaction determined
with the [3H]-PIB preparation. Both SB13 (87 ± 20.96 nM)
and FDDNP (210.17 ± 81.38 nM) demonstrated notably
lower afﬁnity binding interactions which were  20- and
 50-fold weaker than what was observed for BF1.
In summary, these results are consistent with the presence
of at least one class of ligand binding site on the AS ﬁlaments
generated in vitro. This site has a fairly broad ligand binding
speciﬁcity and occurs at low density along the polymer. It is
worth noting that in contrast to our previous studies using Ab
ﬁbrils (Lockhart et al. 2005; Ye et al. 2005), ethanol was
omitted from the buffer as it was found to interfere with the
assay, possibly through destabilisation of the AS polymers.
Ethanol is required to maintain the solubility of these agents
at the higher concentrations (up to 10 lM) used in the
radioligand displacement assays (Lockhart et al. 2005) and
its omission may, in part, explain the increased variability in
the Ki values of the weakest displacers, SB13 and FDDNP.
Ex vivo autoradiography of [3H]-PIB with human brain
tissue containing LB pathology
The presence of binding sites on the AS ﬁlaments raised the
possibility that in vivo LB pathology might contribute to the
uptake and retention of imaging agents such as PIB. In order
to explore this hypothesis further, autoradiography was used
to evaluate the binding of [3H]-PIB to LBs and Lewy neurites
in AMY sections from four individuals with pathologically
conﬁrmed PD (cases A1–A4, Table 2). AMY sections were
chosen, as this brain region is often severely affected by LB
pathology (Braak et al. 1994) and all of the sections used in
the study had high densities of LBs and Lewy neurite
pathologies (Fig. 4a). The concentrations of [3H]-PIB utilised
in this part of the study were chosen to reﬂect the low
nanomolar concentrations of ligand typically attained during
imaging studies (Mathis et al. 2004; Rowe et al. 2007).
Two sets of sections were labelled with tracer concentra-
tions of [3H]-PIB (0.5 and 2 nM) and apposed to ﬁlm for
8 weeks. Three of the four cases analysed showed no
detectable association of the radiolabel with discrete struc-
tures within the neuropil (Fig. 4b–d). Case A4, however,
demonstrated a discrete punctate labelling with [3H]-PIB
(Fig. 4e). The vast majority of the radiolabel associated with
this case was fully displaceable in the presence of unlabelled
competitor ligand (BTA-1, 10 lM) demonstrating that the
labelling was speciﬁc (Fig. 4e inset).
The nature of the pathological features associated with the
radiolabelled areas was investigated further through analysis
of the adjacent sections stained with thioﬂavin S or an anti-
AS antibody. Thioﬂavin S revealed a staining pattern that
was consistent, based on morphology (staining intensity,
shape and size), with the presence of diffuse plaques
(Fig. 4g) and classical plaques (Fig. 4h). These were
distributed across the section, but were most concentrated
in a band running down from the upper, right hand corner. A
high degree of correlation between SP pathology and the
radiolabelled features was demonstrated (Fig. 4f–h).
Staining with the anti-AS antibody indicated that LB
pathology was largely conﬁned to a narrow band of lesions in
the upper right corner of the section. Unfortunately, at this
resolution, and because of the far greater size of the thioﬂavin
S-positive SPs also occupying the same area, it was not
possible to ascertain if LBs corresponded to any of the [3H]-
PIB-labelled lesions. Micro-autoradiography techniques may
provide the necessary higher resolution to dissect out any
potential interaction of [3H]-PIB with LB pathology. How-
ever, taking into account the absence of obvious labelling of
LBsby[3H]-PIBinthethreeotherPDcases,itseemsprobable
that in vivo the cortical uptake of tracer associated with these
lesions will be negligible in comparison with Ab pathology.
Table 1 Summary of binding constant data
from six batches of AS ﬁlaments Kd and Ki values (nM)
Me-BTA1 PIB FDDNP SB13 BF1
AS 4.09 ± 0.82 16.5 ± 4.36 (4.16
#) 210.17 ± 81.38 87 ± 20.96 4.78 ± 0.43*
Ab 4.2
a 25
b, 4.7
c 42
b 6
d 3
a
Comparative literature values for in vitro generated Ab ﬁbrils are shown;
# and * indicates the data
from one or four batches of AS ﬁlaments respectively.
aLockhart et al. 2005;
bYe et al. 2005;
cMathis et al. 2003;
dOno et al. 2002.
Table 2 Pathology scoring of AMY sections and case summaries
associated with [3H]-PIB autoradiography study
Case
number DP CP NFT CAA LB
Clinical
diagnosis
ApoE
status
A1 ))) ) +++ PDD 3/3
A2 ))) ) +++ PDD 2/3
A3 ))) ) +++ PDD 3/4
A4 + ++ ))++ PDD 2/3
DP, diffuse plaques; CP, classical plaques; NFT, neuroﬁbrillary tan-
gles; CAA, cerebrovascular amyloid angiopathy deposits; LB, Lewy
bodies; PDD, Parkinson’s disease with dementia; ApoE, apolipopro-
tein E; AMY, amygdala. Pathology scores: +++, frequent; ++, mod-
erate; +, sparse; ), zero.
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Understanding the biological context of in vivo imaging data
is of crucial importance for an accurate interpretation of the
observed tracer uptake patterns. Research to date in the ﬁeld
of amyloid imaging has concentrated on understanding the
interaction of these tracers with the Ab pathology associated
with AD. The present study focuses on AS ﬁlaments and
provides a number of key ﬁndings directly applicable to
imaging studies performed in dementia patient populations
with concomitant LB pathology (Bacskai et al. 2007;
Johansson et al. 2007; Rowe et al. 2007). It also signiﬁ-
cantly extends previous in vitro studies (Klunk et al. 2003;
Fodero-Tavoletti et al. 2007).
Radioligand binding assays clearly identiﬁed the presence
of a single class of binding sites on AS ﬁlaments to which the
thioﬂavin S chemotypes (PIB, [3H]-Me-BTA-1 and BF1) all
bound with a low nanomolar afﬁnity. SB13 and FDDNP
displayed substantially (> 20-fold) weaker binding to AS
ﬁlaments. These ﬁndings clearly demonstrate that currently
available ligands display a differential selectivity for the
amyloid fold associated with in vitro generated AS ﬁlaments
and provide the basis for a sensitive screening assay to
develop AS-speciﬁc compounds. The results from this study
extend and complement previous in vitro ligand binding
analyses performed with AS ﬁlaments (Conway et al. 2000;
Fodero-Tavoletti et al. 2007).
The study by Conway et al. (2000) demonstrated that
ﬁlaments generated in vitro were both congophilic and able
to enhance thioﬂavin T ﬂuorescence but it did not provide a
detailed analysis of the ligand binding sites. The recent study
by Fodero-Tavoletti et al. (2007) investigated the binding of
[3H]-PIB to in vitro generated AS ﬁlaments using a similar
radioligand binding assay format to the one described here.
However, in contrast to the present study, which found
evidence for only a single site, their data analysis using
(a) (b) (c) (d)
(e) (f) (g)
(h)
Fig. 4 Analysis of amygdala sections from PD cases. (a) Represen-
tative image of section from case A3 showing the extensive immu-
noreactivity to a-synuclein associated with this case. Lewy body
pathology is highlighted with black arrows. (b–d) Low resolution
autoradiographic images of entire amygdala sections from cases A1–
A3. Following labelling with 2 nM [3H]-PIB and ﬁlm exposure of
8 weeks no discrete labelling puncta were observed. (e) Case A4
displayed signiﬁcant punctate labelling with [3H]-PIB. The inset to (e)
demonstrates that the radiolabel is fully displaceable in the presence
of a cold competitor ligand (10 lM BTA-1). (f) High power view of
boxed area in E together with Thioﬂavin S staining of adjacent section
(g and h) indicating the presence of signiﬁcant senile plaque patho-
logy. Arrows show correspondence of diffuse plaques (g) and classical
plaques (h) with [3H]-PIB labelled features. Scale bar: 1 mm.
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AS ﬁlaments. The reasons for this discrepancy are unclear
but may relate to differences in AS ﬁlament preparation,
assay conditions and data analysis. Previously, we observed
a tendency of Scatchard analyses to indicate the presence of
multiple binding sites on Ab ﬁbrils that were not supported
by analysis of the data using non-linear regression (Ye et al.
2006).
The interaction of a range of compounds, including
previously characterised amyloid binding ligands, such as
Me-BTA-1, with AS has also been reported using an assay
format sensitive to potential inhibitors of ﬁlament formation
(Masudaet al.2006b).Although,thebenzothiazolewasfound
to be a weak inhibitor of ﬁlament assembly (IC50 >8 0lM)
this does not preclude its high afﬁnity interaction with the
preformed AS ﬁlaments used in the current study. Further-
more,wefoundnoeffectonASﬁlamentstability(asjudgedby
ultracentrifugation)associatedwithanyoftheamyloidligands
following a 2 h incubation (data not shown).
The density of ligand binding sites was found to be one
ligand binding site per  900 AS monomers. This is
approximately threefold less than the density reported
previously for in vitro generated Ab ﬁbrils (Lockhart et al.
2005) and may reﬂect a fundamental difference in the
quaternary structure of the two polypeptide chains. Conceiv-
ably the observed reduction in binding site density could be
achieved either through a simple reduction in the total
number of binding sites or via steric blockade of a proportion
of the available binding sites by regions of the AS monomer
that are not incorporated in the backbone of the ﬁlament.
Studies of AS ﬁlaments, either generated in vitro or isolated
from brain of DLB patients, have shown that whilst the N-
terminal region of AS is buried within the ﬁlament core, the
C-terminal region is exposed on the ﬁlament surface
(Crowther et al. 2000; Serpell et al. 2000; Chen et al.
2007). Fibre diffraction patterns of synthetic AS ﬁlament
preparations have revealed the presence of a 0.47 nm-
reﬂection at the meridian, characteristic of the cross-b sheet
motif of amyloid (Serpell et al. 2000). These ﬁndings are
consistent with the present observations showing that AS
ﬁlaments can bind to amyloid-speciﬁc ligands such as PIB.
A limited exploration of the structural speciﬁcity of the
radioligand binding site was performed through the use of
displacement assays. However, further investigations into the
presence of additional classes of binding sites similar to those
associated with in vitro preparations of Ab (Levine 2005;
Lockhart et al. 2005; Ye et al. 2005) were not undertaken
because of the relatively narrow range of ligand concentra-
tions that could be explored, because of necessary omission
of ethanol from the assays. The radioligand assays indicated
that all of the compounds examined were able to displace the
radiolabelled BTA derivative and that there were some
potentially signiﬁcant differences in the behaviour of the
competitor ligands. The benzofuran derivative BF1 displayed
both the highest afﬁnity interaction (Ki = 4.78 nM) and the
most consistent displacement, reﬂected in the low variance of
the Ki values measured across different batches of AS. At the
other end of the spectrum, FDDNP displayed the weakest
binding to AS ﬁlaments (Ki = 210 nM) and the greatest
variability across ﬁlament batches. The behaviour of the
stilbene SB13 (Ki = 82 nM) fell somewhere in-between that
of BF1 and FDDNP.
At ﬁrst glance, this would suggest that SB13 and FDDNP
are less selective for AS but, as discussed above, this
difference may be overestimated because of the insolubility
issues encountered when these highly lipophilic compounds
were used at micromolar concentrations (Lockhart et al.
2005). The variability in Ki values may also suggest a degree
of structural heterogeneity between batches of AS ﬁlaments.
Different morphologies have previously been described for
different batches of synthetic AS ﬁlaments (Heise et al. 2005;
Kloepper et al. 2006). It is conceivable that as a result of its
planar structure, FDDNP, the ligand which displayed the
greatest variability, may be more sensitive to this variation.
However, on balance the variability in Ki values can be more
readily explained in terms of individual ligand solubility
rather than potential heterogeneity in ﬁlament structure.
The radioligand binding data also provide an opportunity
to compare ligand afﬁnities between AS ﬁlaments and Ab
ﬁbrils (Table 1). The BTA derivatives and BF1 displayed no
apparent differences in their afﬁnities for either polymer, con-
sistent with very similar binding pockets associated with both
amyloid ﬁlaments. Only FDDNP and SB13 presented large
differences (> 5-fold) between AS and Ab polymers, and
although this might be because of differences in assay format,
it nevertheless raises the possibility of engineering selectivity
for the different neuropathological amyloid structures.
The autoradiography study clearly demonstrated that tracer
concentrations of PIB did not bind to the extensive LB
pathology associated with AMY sections. Although some
caution must be observed, given the relatively small number
of cases and brain regions examined, the data nevertheless
indicate that in vivo LBs are unlikely to contribute signif-
icantly to the cortical uptake of PIB. These results signiﬁ-
cantly extend the previous, essentially histological, evaluation
of PIB binding to LB pathology (Fodero-Tavoletti et al.
2007) which used ﬁxed tissue, extensive tissue preparation
techniques and ﬂuorescence microscopy with a high con-
centration of ligand (100 lM). In contrast, the current study
used fresh-frozen brain sections and minimal tissue prepara-
tion techniques in an effort to maintain the integrity of
pathological features to as close as in vivo as possible. In
addition radiotracer concentrations directly relevant to in vivo
imaging were utilised and we believe that combined these
factors signiﬁcantly reduced the potential for a false, negative
signal from this part of the study.
The lack of detectable binding of [3H]-PIB to the LB
pathology contrasts with the high-afﬁnity binding sites on
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binding assays. However, as discussed above, the density of
ligand binding sites associated with AS ﬁlaments was around
threefold lower than that previously detected on synthetic Ab
ﬁbrils (Klunk et al. 2003; Lockhart et al. 2005; Ye et al.
2005). It is conceivable that this lower concentration of bind-
ing sites is maintained in vivo on the AS ﬁlaments associated
with LBs and that this, in turn, may lead to a low sensitivity of
the tracer for this lesion. In contrast, the number of ligand
binding sites associated with Ab ﬁbrils in vivo appears to be
an order of magnitude higher than that found on ﬁbrils
producedinvitro(Klunket al.2003,2005).Potentialconcerns
over the ability of autoradiography to detect ﬁne, microscopic
lesions can be partly addressed, as an identical method was
previously used to detect NFTs (Lockhart et al. 2007).
A number of factors may act to reduce the number of
available in vivo binding sites; they include post-translational
modiﬁcations of the AS and the presence of accessory
proteins within the LBs. Although no study has addressed
these issues so far (for any lesion) they could either
chemically modify the binding site or simply produce steric
hindrance to ligand binding. In LBs, at least some AS
ﬁlaments are extensively phosphorylated and nitrated, in
addition to being ubiquitinated (Goedert 2001; Kotzbauer
et al. 2001). These modiﬁcations could in principle produce
conformational changes within the ﬁlament structure.
In summary, this study provides the ﬁrst detailed descrip-
tion of the interaction of imaging tracers with an amyloid
pool other than ﬁbrillar Ab and additionally, complements
the developing literature surrounding the application of
amyloid agents in non-AD dementia patient populations such
as DLB (Bacskai et al. 2007; Rowe et al. 2007). The present
report provides comprehensive evidence indicating that
although AS ﬁlaments possess binding sites compatible with
current amyloid imaging probes, in vivo LBs are unlikely to
represent a major source of cortical tracer uptake. In addition,
this study provides further speciﬁc support to the observation
that in vivo PIB is likely to be a non-disease speciﬁc imaging
marker of Ab peptide-related cerebral amyloidosis (Lockhart
et al. 2007). Finally, the data suggest that the development of
AS-speciﬁc probes, although feasible, will require signiﬁcant
investment in both biology and radiochemistry.
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